Dexamethasone bioerodible implant - iVeena Delivery Systems

Drug Profile

Dexamethasone bioerodible implant - iVeena Delivery Systems

Alternative Names: IVMED-10; IVMED-20

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Utah Research Foundation
  • Developer iVeena Delivery Systems; University of Utah Research Foundation
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Inflammation
  • Preclinical Retinal oedema

Most Recent Events

  • 24 Nov 2017 Chemical structure information added
  • 08 Nov 2017 Preliminary safety data from a phase I/IIa trial in Inflammation released by iVeena Delivery Systems
  • 08 Nov 2017 iVeena Delivery Systems completes a phase I/IIa trial in Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top